Teva- Pharmaceutical Industries Ltd. - ADR
TEVA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$50.88B
Close$
Earnings Call Q3 2026
November 3, 2026 - AI Summary
Strong Q3 “pivot to biopharma” performance + raised 2026 guidance
- Revenue $4.4B (-2% YoY), but gross margin rose to 58.7% (+~345 bps YoY) and non-GAAP EPS +10% (free cash flow $495M, slightly below prior year).
- Innovative portfolio +33% YoY; generics -16% YoY largely due to low Generic REVLIMID contribution (and divested Japan impact).
- 2026 guidance raised: revenue to $16.7B–$17.0B; AUSTEDO $2.55B–$2.65B, AJOVY $930M–$960M, UZEDY $290M–$310M.
- Operating margin trajectory reiterated: reaching ~30% operating margin by 2027 (with IPR&D excluded to show underlying progress).
UZEDY launch is a major milestone (and viewed as “no-loading” differentiation)
- FDA approval/launch of UZEDY (LAI for schizophrenia): once-monthly subcutaneous olanzapine with no loading dose, no oral supplementation, and no post-injection monitoring.
- Q3: UZEDY revenue $85M (+96% YoY); TRX and LAT +62% YoY.
- Commercial traction: UZEDY nearly doubled risperidone LAI share (5%→10%) and captures ~83% of risperidone LAI.
- Guidance lifted + $20M at midpoint to $290M–$310M; management positions this as solid foundation for WELTRUZA launch.
AUSTEDO momentum is strong—guidance supports resilience despite IRA headwinds
- AUSTEDO hit its $2.5B target one year ahead of schedule.
- Q3: AUSTEDO $751M (+21% YoY); U.S. TRx +18%, milligram dispense +23%.
- Outlook: raised 2026 to $2.55B–$2.65B; management expects Q4 down YoY due to IRA-related purchasing/pricing dynamics.
- Most notable investor “risk/offset” narrative: management says there are fundamentals offsetting IRA impact and expects AUSTEDO ~$2.5B in 2027 and > $3B at peak (but no detailed 2027 guidance provided).
Exclusive for Stockcircle Pro members
Sign up
$13.07
70.1% downside
Current Fair Value
70.1% downsideOvervalued by 70.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $50.88 Billion |
|---|---|
| Enterprise Value | $63.78 Billion |
| Earnings per Share | $1.23 |
| Beta | 0.84 |
| Outstanding Shares | 1,166,000,000 |
Return
| Return on Equity | 6.34% |
|---|---|
| Return on Assets | 1.26% |
| Return on Invested Capital | 5.09% |
Valuation & Multiples
| P/E Ratio | 94.69 |
|---|---|
| PEG | -205 |
| Price to Sales | 3.12 |
| Price to Book Ratio | 7.27 |
| Enterprise Value to Revenue | 3.7 |
| Enterprise Value to EBIT | 50.91 |
| Enterprise Value to Net Income | 126 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 2.13 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$0.71
Consensus analyst estimateRevenue Estimate
$4.28 B
Consensus analyst estimateNext Earnings Call
Expected Date
January 27, 2027
EPS Estimate
$0.70
Consensus analyst estimateRevenue Estimate
$4.26 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 4.91, the ratio is above 1, so institutions hold more puts than calls. That is a more cautious stance.
| Put/Call Ratio | 4.9094▲ 439.75% |
|---|---|
| Total Calls | 8,168▼ 99.96% |
| Total Puts | 40,100▼ 99.58% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.08%▼ 53.08% |
|---|---|
| Total Invested | $4.68B▼ 81.14% |
| Investors Holding | 264▼ 452.00% |
About Teva- Pharmaceutical Industries Ltd.
33,346 employees
CEO: Kaare Schultz
Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products througho...